Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNF4 | P78317 | 1/20 | 0.51 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 5/20 | 0.42 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.42 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.41 |
| ▸ | PTGES | O14684 | 3/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1259043 | 0.84 | CDK8 (0.41) | CDK8PDK1 | |
| SCHEMBL1258201 | 0.83 | CDK8 (0.47) | CDK8 | |
| SCHEMBL1260165 | 0.81 | ALDH1A1 (0.48) | RNF4NR3C1GAATSHRPTGES | |
| SCHEMBL1260162 | 0.81 | ALDH1A1 (0.48) | RNF4NR3C1GAATSHRPTGES | |
| SCHEMBL1478338 | 0.77 | CDK8 (0.46) | CDK8 | |
| SCHEMBL1259495 | 0.76 | RNF4 (0.46) | RNF4NR3C1GAATSHRSERPINE1 | |
| SCHEMBL1826466 | 0.75 | MAOA (0.56) | TSHRCDK8 | |
| SCHEMBL4443147 | 0.74 | NPC1 (0.54) | GAATSHRPDK1SMN1; SMN2 | |
| SCHEMBL1259881 | 0.73 | KDM4E (0.50) | RNF4NR3C1PTGESALOX5SMN1; SMN2 | |
| SCHEMBL1927016 | 0.72 | ALDH1A1 (0.69) | GAATSHRPDK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110046169-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046169-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | ABL1, MAP4K2, MAP3K20 | RNF4 2307/4885NR3C1 1173/4885GAA 3285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.